After a unanimous panel vote, will Spark’s novel gene therapy be a $1 million drug? – STAT
STAT |
After a unanimous panel vote, will Spark's novel gene therapy be a $1 million drug?
STAT If the panel votes yes and the FDA follows its recommendation, Luxturna would become the first therapy meant to replace or repair a defective gene approved in the U.S. Spark hasn't disclosed pricing, but analysts estimate Luxturna could cost $1 million … |
